



0590
1000

Docket No. 2026-4006US5

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Pavlakis et al. Group Art Unit: TBA
Serial No. : 09/943,722 Examiner: TBA
Filed : August 31, 2001
For : METHOD OF ELIMINATING INHIBITORY/INSTABILITY
REGIONS OF mRNA

TRANSMITTAL LETTER

U.S. Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

Sir:

Transmitted herewith is:

1. Express Mail Certificate, including Express Mail Label No. EL762621785US
2. Information Disclosure Statement (2 copies) (no fee)
3. Information Disclosure Citation (Form PTO-1449), including cited references
4. Return Receipt Postcard

The Commissioner is hereby authorized to charge any additional fees which may be required by any of these papers, or credit any overpayment to Deposit Account No. 13-4500, Order No. 2026-4006US5. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.


Respectfully submitted,
MORGAN & FINNEGAN, L.L.P.

Dated: November 30, 2001

Mailing Address:
MORGAN & FINNEGAN, L.L.P.
345 Park Avenue
New York, New York 10154
(212) 758-4800

By: Mary J. Morry

Mary J. Morry
Registration No. 34,398



Docket No. 2026-4006US5

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Pavlakis, et al.
Serial No. : 09/943,722 Examiner: TBA
Filing Date : August 31, 2001 Art Unit: TBA
For : **METHOD OF ELIMINATING
INHIBITORY/INSTABILITY REGIONS OF mRNA**

EXPRESS MAIL CERTIFICATE

Express Mail Label No.: EL762621785US
Date of Deposit: November 30, 2001


I hereby certify that the following attached paper(s) and/or fee

1. Transmittal Letter (2 copies)
2. Information Disclosure Statement (2 copies) (no fee)
3. Information Disclosure Citation (Form PTO-1449), including cited references
4. Return Receipt Postcard

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to the U.S. Patent and Trademark Office, P.O. Box 2327, Arlington, VA 22202.

Jesus R. Remedios

(Typed or printed name of person mailing papers(s) and/or fee)



(Signature of person mailing paper(s) and/or fee)

Correspondence Address:

MORGAN & FINNEGAN, L.L.P.
345 Park Avenue
New York, NY 10154-0053
(212) 758-4800 Telephone
(212) 751-6849 Facsimile

#4/IDS



PATENT

Docket No. 2026-4006US5

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Pavlakis, et al.
Serial No. : 09/943,722 Examiner: TBA
Filing Date : August 31, 2001 Art Unit: TBA
For : **METHOD OF ELIMINATING INHIBITORY/
INSTABILITY REGIONS OF mRNA**

INFORMATION DISCLOSURE STATEMENT


U.S. Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

Sir:


This Information Disclosure Statement is filed in accordance with 37 C.F.R. §§1.56, 1.97 and 1.98.

The items listed on Form PTO-1449, a copy of which is enclosed, may be deemed to be pertinent to the above-identified application and are made of record to assist the Patent and Trademark Office in its examination of this application. The Examiner is respectfully requested to fully consider the items and to independently ascertain their teaching.

1. ☒ For each of the following items listed on the enclosed copy of Form PTO-1449 that is not in the English language, an English language translation of that item or a portion thereof or a concise explanation of the relevance of that item is enclosed:
Japanese articles for Reference No. 4, Reference No. 6 and Reference No. 7
2. ☐ For each of the following items listed on the enclosed copy of Form PTO-1449 that is not in the English language, a concise explanation of the relevance of that item is incorporated in the specification of the above-identified application.
3. ☐ Any copy of the items listed on the enclosed copy of Form PTO-1449 that is not enclosed with this Information Disclosure Statement was previously cited by or submitted to the Patent and Trademark Office in application Serial No. _____, filed _____.
4. ☒ No fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with:



- ☒ 37 C.F.R. §1.97(b)(1), within three months of the filing date of the above-identified application or filing date of the continued prosecution application filed on _____; or
- ☐ 37 C.F.R. §1.97(b)(2), within three months of the date of entry into the national stage as set forth in §1.491 in an international application; or
- ☒ 37 C.F.R. §1.97(b)(3), before the mailing date of a first Office Action on the merits, whichever event occurred last.
5. ☐ No fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(c), after the period specified in paragraph 4 above but before the mailing date of a final action or a Notice of Allowance (where there has been no prior final action), and is accompanied by one of the certifications pursuant to 37 C.F.R. §1.97(e) set forth in paragraph 9 below.
6. ☐ A fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(c), after the period specified in paragraph 4 above but before the mailing date of a final action or a notice of allowance (where there has been no prior final action):
- ☐ A check in the amount of \$____ is enclosed in payment of the fee.
- ☐ Charge the fee to Deposit Account No. 13-4500. Order No. _____. A
DUPLICATE COPY OF THIS SHEET IS ATTACHED.
7. ☐ A fee is due under 37 C.F.R. §1.17(i)(1) for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(d), after the mailing date of a final action or a notice of allowance, whichever comes first, but before payment of the issue fee, and is accompanied by:
- a. ☐ one of the certifications pursuant to 37 C.F.R. §1.97(e) set forth in paragraph 9 below; and
- b. ☐ the attached petition requesting consideration of this Information Disclosure Statement; and
- c. ☐ the fee due under 37 C.F.R. §1.17(i)(1) which is paid as set forth in paragraph 10 below.
8. ☐ A fee is due under 37 C.F.R. §1.17(i)(1) for this Information Disclosure Statement since it is being filed in compliance with:
- a. ☐ 37 C.F.R. §1.313(b)(3), after the issue fee has been paid and information cited in this Information Disclosure Statement may render at least one claim unpatentable and is accompanied by the attached Petition To Withdraw Application From Issue;
- b. ☐ 37 C.F.R. §1.313(b)(5), after the issue fee has been paid and information cited in this Information Disclosure Statement is to be considered in a Continuation application upon abandonment of the instant application and is accompanied by the attached Petition To withdraw Application From Issue.
- c. ☐ The fee due under 37 C.F.R. §1.17(i)(1) is paid as set forth in paragraph 10 below.
9. ☐ I hereby certify that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.
- ☐ I hereby certify that no item of information in the Information Disclosure Statement field herewith was cited in a communication from a foreign patent office in a counterpart foreign



application or, to my knowledge after make reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

10. ☐ A check in the amount of \$130.00 is enclosed in payment of the fee due under C.F.R. §1.17(i)(1).

☐ Charge the fee due under C.F.R. §1.17(i)(1) to Deposit Account No. 13-4500. Order No. _____ A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

☒ The Assistant Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. 13-4500. Order No. 2026-4006US5. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

Respectfully submitted,

MORGAN & FINNEGAN, L.L.P.

Dated: November 30, 2001

By: _____

Mary J. Morry
Registration No. 34,398

CORRESPONDENCE ADDRESS:
MORGAN & FINNEGAN, L.L.P.
345 Park Avenue
New York, New York 10154
(212) 758-4800
(212) 751-6849 Facsimile

FORM: IDS.NY
Rev. 05/26/98